Video Legends
Segment 1. 55-year old Parkinson’s disease patient who developed peak-dose dyskinesias
after the first-ever levodopa dose; disease duration was 6 years. Brain CT was normal.
Segment 1A: OFF-state; UPDRS part II 8/48, part III 19/108; Hoehn and Yahr 2/5. Segment
1B: ON-state, 90 minutes after levodopa 150 mg (2.2 mg/kg); UPDRS III 6/108.
Segment 2A. Baseline assessment of a 69-year old Parkinson’s disease patient with 12-year
history of untreated Parkinson’s disease and severe motor disability (OFF-state UPDRS III
50/108; Hoehn and Yahr 4/5). Segment 2B. The same patient, 24 hours after the introduction
of levodopa (ON-state UPDRS III 18/108; Hoehn and Yahr 2/5). Now the patient is no longer
shuffling while walking and is able to run; note the improved arm swings. He soon developed
wearing-off (3 hours after levodopa intake), while dyskinesias took several days to develop.
Segment 2C. At the 3-month follow-up, peak-dose dyskinesias developed (ON-state UPDRS
III 7/108; Hoehn and Yahr 2/5); levodopa dose was 600 mg/day (150 mg four times/day,
6.5mg/kg/day).